Showing results (181-190 of 241) with videos related to
Sort By:
Pageof 25
Blood|October 2, 2024
Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trialSari Kytölä, Ida Vänttinen, Tanja Ruokoranta, et al.Stem Cells and Development|December 1, 2007
Alpha10 integrin expression is up-regulated on fibroblast growth factor-2-treated mesenchymal stem cells with improved chondrogenic differentiation potentialLaura Varas, Lars Bryngelson Ohlsson, Gabriella Honeth, et al.Blood|January 1, 2005
Deficiency of ribosomal protein S19 in CD34+ cells generated by siRNA blocks erythroid development and mimics defects seen in Diamond-Blackfan anemiaJohan Flygare, Thomas Kiefer, Koichi Miyake, et al.American Journal of Hematology|January 11, 2022
Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register studyTorsten Dahlén, Gustaf Edgren, Per Ljungman, et al.The Hematology Journal : the Official Journal of the European Haematology Association|December 1, 2004
Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia: BMT prolongs survivalUlla Olsson-Strömberg, Bengt Simonsson, Tomas Ahlgren, et al.Haematologica|December 15, 2022
Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemiaHeikki Kuusanmäki, Sari Kytölä, Ida Vänttinen, et al.European Journal of Haematology|May 31, 2022
Efficacy of conventional-dose cytarabine, idarubicin and thioguanine versus intermediate-dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long-term results of the prospective randomized nationwide AML-2003 study by the Finnish Leukemia GroupAarne Kolonen, Marjatta Sinisalo, Heini Huhtala, et al.Journal of the National Cancer Institute|March 6, 2016
Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United StatesWilliam V Padula, Richard A Larson, Stacie B Dusetzina, et al.Bone|August 3, 2013
Lentiviral gene transfer of TCIRG1 into peripheral blood CD34(+) cells restores osteoclast function in infantile malignant osteopetrosisIlana Moscatelli, Christian Schneider Thudium, Carmen Flores, et al.ESMO Open|January 21, 2020
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignanciesBarbara Kiesewetter, Nathan I Cherny, Nicolas Boissel, et al.Pageof 25